118-13-8 Usage
Description
3-Hydroxyquinoline-4-carboxylic acid is an organic compound with the molecular formula C10H6NO4. It is a derivative of quinoline, featuring a hydroxyl group at the 3rd position and a carboxylic acid group at the 4th position. 3-HYDROXYQUINOLINE-4-CARBOXYLIC ACID is known for its potential applications in various fields due to its unique chemical structure and properties.
Uses
Used in Pharmaceutical Industry:
3-Hydroxyquinoline-4-carboxylic acid is used as a reactant for the preparation of benzazepinones and benzoxazepinones. These compounds serve as inhibitors of Apoptosis Proteins (IAPs), which play a crucial role in regulating cell survival and apoptosis. By targeting IAPs, these antagonists can potentially be used in the development of therapeutic agents for various diseases, including cancer.
Check Digit Verification of cas no
The CAS Registry Mumber 118-13-8 includes 6 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 3 digits, 1,1 and 8 respectively; the second part has 2 digits, 1 and 3 respectively.
Calculate Digit Verification of CAS Registry Number 118-13:
(5*1)+(4*1)+(3*8)+(2*1)+(1*3)=38
38 % 10 = 8
So 118-13-8 is a valid CAS Registry Number.
InChI:InChI=1/C10H7NO3/c12-8-5-11-7-4-2-1-3-6(7)9(8)10(13)14/h1-5,12H,(H,13,14)
118-13-8Relevant articles and documents
A tautomeric ligand enables directed C-H hydroxylation with molecular oxygen
Li, Zhen,Wang, Zhen,Chekshin, Nikita,Qian, Shaoqun,Qiao, Jennifer X.,Cheng, Peter T.,Yeung, Kap-Sun,Ewing, William R.,Yu, Jin-Quan
, p. 1452 - 1457 (2021/06/30)
Hydroxylation of aryl carbon-hydrogen bonds with transition metal catalysts has proven challenging when oxygen is used as the oxidant. Here, we report a palladium complex bearing a bidentate pyridine/ pyridone ligand that efficiently catalyzes this reaction at ring positions adjacent to carboxylic acids. Infrared, x-ray, and computational analysis support a possible role of ligand tautomerization from monoanionic (L,X) to neutral (L,L) coordination in the catalytic cycle of aerobic carbon-hydrogen hydroxylation reaction. The conventional site selectivity dictated by heterocycles is overturned by this catalyst, thus allowing late-stage modification of compounds of pharmaceutical interest at previously inaccessible sites.
